<SEC-DOCUMENT>0001269026-16-000103.txt : 20160223
<SEC-HEADER>0001269026-16-000103.hdr.sgml : 20160223
<ACCEPTANCE-DATETIME>20160223092049
ACCESSION NUMBER:		0001269026-16-000103
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160223
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160223
DATE AS OF CHANGE:		20160223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMEDICA Corp
		CENTRAL INDEX KEY:			0001269026
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33624
		FILM NUMBER:		161446987

	BUSINESS ADDRESS:	
		STREET 1:		1885 WEST 2100 STREET
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84119
		BUSINESS PHONE:		801-839-3516

	MAIL ADDRESS:	
		STREET 1:		1885 WEST 2100 STREET
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84119

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMEDICA CORP
		DATE OF NAME CHANGE:	20031104
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a20160223_8-k.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>8-K</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sbd7b99caff304b9f93578ff9f3070862"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM&#160;8-K</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of report (Date of earliest event reported): February 23, 2016</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">Amedica Corporation</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="32%"></td><td width="2%"></td><td width="32%"></td><td width="2%"></td><td width="32%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">001-33624</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">84-1375299</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">File Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="49%"></td><td width="2%"></td><td width="49%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1885 West 2100 South</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Salt Lake City, UT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">84119</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant&#8217;s telephone number, including area code: </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(801) 839-3500</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former Name or Former Address, if Changed Since Last Report)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">see</font><font style="font-family:inherit;font-size:10pt;">&#32;General Instruction A.2. below):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160; Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160; Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160; Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160; Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;"><hr></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sbd7b99caff304b9f93578ff9f3070862"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01 Other Events.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 23, 2016, Amedica Corporation issued a press release announcing its participation in the 2016 Brazilian Spine Congress occurring March 3-4, 2016 in Sao Paulo, Brazil. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01 Financial Statements and Exhibits.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;&#160;&#160;&#160;&#160; Exhibits.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1&#160;&#160;&#160;&#160;Amedica Corporation Press Release dated February 23, 2016.</font></div><div style="line-height:174%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sbd7b99caff304b9f93578ff9f3070862"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURE</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="50%"></td><td width="50%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AMEDICA CORPORATION</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: February 23, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ty Lombardi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ty Lombardi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a20160223_ex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s326d3353c30f4f63be97d5835adeb960"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit 99.1</font></div><div style="line-height:120%;"><img src="amedica2.gif" style="height:89px;width:165px;"></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Amedica to Present Advantages of Silicon Nitride Implants at 2016 Brazilian Spine Congress</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">Company Experiences Positive Sales Impact from Recent Brazil Clearance</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SALT LAKE CITY,&#160;February 23, 2016 -&#160;Amedica Corporation&#160;(Nasdaq:AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, is pleased to announce its participation in the 2016 Brazilian Spine Congress occurring March 3-4, 2016 in Sao Paulo, Brazil. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;Brazil has been an emerging growth opportunity for us since achieving clearance during the third quarter of last year thanks in part to our Brazilian partner, Sintex Medical,&#8221; said Dr. Sonny Bal, Chairman and Chief Executive Officer. &#8220;We feel that the content we plan to present, and the surgeons with whom we will be meeting in Sao Paulo will strengthen this additional sales channel through the balance of this year.&#8221; </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">"With the limited options currently available to Brazilian surgeons, Brazil reflects a market opportunity for new technologies in spinal products and surgical techniques,&#8221; said Daniel Bolotnicki, Chief Executive Officer of Sintex Medical. &#8220;We&#8217;ve experienced very positive feedback with the silicon nitride fusion devices since our initial launch last quarter, due in part to the unique osteoconductive, anti-infective, and superior imaging properties of silicon nitride. We anticipate further geographic expansion, and expect to capture a significant share of the market from legacy PEEK cages that have inherent limitations. We are confident the Brazilian market will understand the superiority of silicon nitride, in terms of positively affecting patient outcomes.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;I look forward to presenting and sharing the clinical outcomes I&#8217;ve experienced while using silicon nitride the past several years,&#8221; said Dr. Graham C. Calvert, M.D., Mississippi Sports Medicine and Orthopedic Center. &#8220;Silicon nitride truly is a breakthrough material and contains a unique surface biochemistry which ensures reliable osseointegration, while also inhibiting bacterial biofilm adhesion.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The 16</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;annual Brazilian Spine Congress attracts leading clinicians, surgeons, and scientists from the Americas who come together to present the latest innovative musculoskeletal clinical and scientific research. For more information on the Brazilian Spine Congress, please visit </font><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">http://cirurgiaespinhal.com.br/2016/</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About&#160;Amedica Corporation</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Amedica is focused on the development and application of interbody implants manufactured with medical-grade silicon nitride ceramic. Amedica markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip and knee arthroplasty as well as dental applications. The Company&#8217;s products are manufactured in its ISO 13485 certified manufacturing facility and through its partnership with Kyocera, one of the world's largest ceramic manufacturers. Amedica's spine products are FDA-cleared, CE-marked, and are currently marketed in the U.S. and select markets in Europe and South America through its distributor network and its growing OEM and private label partnerships.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">For more information </font><font style="font-family:inherit;font-size:11pt;">on Amedica or its silicon nitride material platform, please visit&#160;</font><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">www.amedica.com</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Forward-Looking Statements </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include, but are not limited to, the intent, belief or </font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s326d3353c30f4f63be97d5835adeb960"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">current expectations of Amedica and members of its management team with respect to Amedica's future performance, business operations and acceptance of its technology platform. Statements relating to Amedica's market opportunities, growth, future products, market acceptance of its products, sales and financial results and similar statements are subject to risks and uncertainties such as the timing and success of new product introductions, physician acceptance, endorsement, and use of Amedica's products, regulatory matters, competitor activities, changes in and adoption of reimbursement rates, potential product recalls, effects of global economic conditions and changes in foreign currency exchange rates. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found in Amedica's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 24, 2015, and in Amedica's other filings with the SEC. Amedica disclaims any obligation to update any forward-looking statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Contacts:</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mike Houston</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">VP, Commercialization </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">801-839-3534</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">IR@amedica.com</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Robert Haag</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IRTH Communications</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">866-976-4784</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">amda@irthcommunications.com</font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>amedica2.gif
<TEXT>
begin 644 amedica2.gif
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M+6XR5D1A!1WHY(M.!$'^0T<#%)3(T887))-! Q@2_R2( Q5 DT$!*F)D10"
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M"\;0"P'G#2J ",^P!UFP#7*P)LVP!V&P#&80!KV@"]$0#FGP!0?[H_$& X@
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7XCN^Y%N^YGN^Z)N^ZKN^[-N^>A00 #L!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
